Research
Mixed
The EMP16 combination therapy significantly improves the Fatty Liver Index (FLI) and reduces visceral adiposity index (VAI) more effectively than conventional orlistat, suggesting specific benefits for liver health beyond general weight loss.
If you have fatty liver or high visceral fat, this specific combination pill (EMP16) may offer better liver health improvements than standard orlistat. It significantly reduces the Fatty Liver Index compared to conventional treatments.
GoodSupportsHIGH confidence
Participants on EMP16- 120/40 had a larger decrease in FLI compared to participants on MR- O (p = 0.047) and Conv- O (p < 0.001)... Participants on EMP16 had a lower VAI compared to participants on Conv- O at the end of the trial (Table 2, p = 0.014).
Why this rating
Randomized controlled trial data, though FLI is a surrogate marker.
Source
The Supportive Effect of Acarbose to Orlistat in Weight Management—A Randomized, Double‐Blind, Multiarm Phase 2 Trial
Ulf Holmbäck et al. · Obesity · 2025
rct · n=240
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →